Navigation Links
Biopure Receives Notices About Nasdaq Listing Compliance
Date:3/31/2009

CAMBRIDGE, Mass., March 31 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that it has received several notices from The Nasdaq Stock Market. By letter dated March 24, 2009, Nasdaq advised that, as the company had not yet filed its Form 10-Q for the fiscal quarter ended January 31, 2009, it was out of compliance with the Nasdaq Marketplace Rules. The company filed the report and received a letter dated March 26, 2009, stating that the matter was closed.

NASDAQ also notified the company that it has suspended enforcement of its minimum bid price and market value requirements for continued listing, thereby extending the company's time in which to regain compliance. Enforcement of these rules is scheduled to resume on July 20, 2009. The company estimates, that it now has until September 12, 2009, to regain compliance with the $1.00 minimum bid price requirement. If at any time before that date the bid price of the company's common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the company should be provided written notification that it complies with the Marketplace Rules.

Biopure Corporation

Biopure Corporation develop and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. On November 21, 2008, the company announced that it had suspended manufacturing and terminated most of its work force for financial reasons. The company may not be able to continue as a going concern. Using its limited resources, the company is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trau
'/>"/>

SOURCE Biopure Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Biopure Exploring Strategic Options
2. Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance
3. Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia
4. Biopure Sues National Institutes of Health Official
5. Agency Takes Adverse Decision to Biopures Product Registration in South Africa
6. Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance
7. Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop
8. Biopure Receives Comment Letter From U.K. Regulatory Body on Marketing Application for Hemopure(R)
9. Biopure Announces 2007 Fourth Quarter and Year-End Financial Results
10. Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
11. Biopure Announces Closing of $14.9 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... When Mary Ann Thompson and Mathieu Nikel decided it was ... Indonesia with their son, Isaac, said there was only one choice ... College in 2001 when Thompson was an undergraduate student and needed ... at the time, was French and so she asked him. ... United States when she was 7 years old. Nikel is ...
(Date:9/18/2014)... 18, 2014 Active Aging Week is ... as fully participating members of society and promotes the ... The Stafford – a boutique retirement community located at ... host two screenings of Cyber-Seniors - a humorous and ... residents to watch this great film,” says Thomas Cloutier, ...
(Date:9/18/2014)... cancer experts around the world have issued a plea ... carry out high quality research and clinical trials for ... fatal and for which there are many unanswered questions. ... management of advanced breast cancer, published simultaneously in the ... Annals of Oncology [1] today (Friday), the experts ...
(Date:9/18/2014)... Memorial Cardiac and Vascular Institute ... by performing the first ever, adult heart transplant in ... Organ Sharing) approval to launch the adult heart transplant ... programs in South Florida. , The skilled cardiac ... Medical Director of the Adult Heart Transplant and ...
(Date:9/18/2014)... 19, 2014 A jacket is a ... jacket typically has sleeves, and fastens in the front ... lighter, tighter-fitting, and less insulating than a coat, which ... as protective clothing. Today, Fecbek, a well-known clothing manufacturer ... trendy men’s jackets; all these items are offered at ...
Breaking Medicine News(10 mins):Health News:For The First Time in Over a Decade Mercy College Alumni Marry at College 2Health News:In Support of Active Aging Week, a Lake Oswego Retirement Community Will Get a Sneak Peek at an Inter-Generational Documentary – Cyber-Seniors 2Health News:Experts issue plea for better research and education for advanced breast cancer 2Health News:Experts issue plea for better research and education for advanced breast cancer 3Health News:Experts issue plea for better research and education for advanced breast cancer 4Health News:Experts issue plea for better research and education for advanced breast cancer 5Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 4Health News:Cool Jackets Are For Sale At Fecbek.com 2
... US biomedical engineering team has announced the development of ... an ability to deliver a visual acuity of about ... camera and an ultrasonic distance sensor, both of which ... connect through a cable to a miniature computer which ...
... AIDS research at the moment is the research to treat ... into this project have developed a lot of interest in ... with genes in mind. , ... some people who are infected with the dreaded human immuno-deficiency ...
... may be round the corner as scientists have traced the pathway ... start with they have experimented on the rat brain and they ... time that such advances have been made vis-à-vis eating disorders. ... of brain cells respond to hormones, among them two proteins called ...
... lives of millions, scientists at the University of Scarthclyde and ... protein based drugs such as insulin using inhalers. , ... coated micro crystals can pass through the lung wall and ... those used by asthma sufferers.// , ...
... in the pipeline to reduce risk factors of heart disease, ... attacks. Dr. Carl R. Alving of the Walter Reed Army ... various infectious agents in the development of atherosclerosis, or hardening ... reduce heart disease risk factors such as high cholesterol. ...
... A new breakthrough using gene therapy mouthwash promises good results ... cancer by destroying suspicious growths in the mouth before they ... by unleashing viruses, which kills cells that contain cancer-causing genes. ... is the first study of its kind, scientists are enthusiastic, ...
Cached Medicine News:Health News:Fight oral cancer with gene therapy mouthwash, 2
(Date:9/18/2014)... 18, 2014 MiMedx Group, Inc. (NASDAQ: ... and marketer of patent protected regenerative biomaterials and ... that it has entered into a distribution agreement ... provide its dehydrated human amnion/chorion membrane ("dHACM") allograft ... on a private label basis. The ...
(Date:9/18/2014)... DIEGO , Sept. 18, 2014  Halozyme ... announced that the U.S. Food and Drug Administration ... enrollment and dosing of PEGPH20 in SWOG,s ongoing ... designed to evaluate Halozyme,s investigational drug PEGPH20 (PEGylated ... chemotherapy (mFOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma.  ...
(Date:9/18/2014)... , Sept. 18, 2014 Relmada Therapeutics, ... for the treatment of chronic pain, announced today that ... to the position of  Senior Director of Clinical Development. ... Mr. James has established and led successful global clinical ... , to facilitate the clinical development of numerous ...
Breaking Medicine Technology:MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:Sensitech's Groundbreaking TempTale(R)4 USB Dry Ice Temperature Monitor Provides Fast, Simple, Efficient Cold Chain Visibility 2Sensitech's Groundbreaking TempTale(R)4 USB Dry Ice Temperature Monitor Provides Fast, Simple, Efficient Cold Chain Visibility 3Sensitech's Groundbreaking TempTale(R)4 USB Dry Ice Temperature Monitor Provides Fast, Simple, Efficient Cold Chain Visibility 4Sensitech's Groundbreaking TempTale(R)4 USB Dry Ice Temperature Monitor Provides Fast, Simple, Efficient Cold Chain Visibility 5China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 2China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 3China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 4China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 5China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 6China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 7China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 8China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 9China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 10China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 11China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 12China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 13China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 14China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 15China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 16China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 17China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 18China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 19China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 20China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 21China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 22China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 23China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 24China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 25China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 26China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 27
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: